Fluoxetine in tricyclic refractory major depressive disorder

Beasley, Charles M.; Sayler, Mary E.; Cunningham, Gregory E.; Weiss, Alan; Masica, Daniel N.

doi:10.1016/0165-0327(90)90144-w

Cited by 48 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beasley et al [25] reported that 18 of the 35 TCA nonresponders responded to fluoxetine 60–80 mg daily. Reimherr et al [21] reported that 17 of 40 such patients improved with a switch from TCA to fluoxetine 60–80 mg daily.…”

Section: Treatmentmentioning

confidence: 99%

Treatment-Resistant Depression

Ananth

1998

Psychother Psychosom

View full text Add to dashboard Cite

Our ability to treat depression has improved with the availability of receptor-specific and chemically diverse groups of antidepressants. Even now, most of the short-term studies indicate that about 20% of depressed patients remain resistant to treatment. Therefore, it is important to properly assess the treatment-resistant depressed (TRD) patients and to separate the truly refractory patients from those inadequately treated. Undiagnosed medical conditions should be eliminated. TRD is neither a clinically nor a biologically identifiable entity. As there are no established methods for the treatment of TRD, all options should be considered. The clinician can be enriched by the knowledge of the treatment modalities available, and yet, in treating an individual patient, clinical skills, intuitive judgment, family history of response to drugs and side effects, all play a vital role. Several of the approaches described in the paper indicate available methods and their merits in general but there is no way of ascertaining by which particular method a patient should be treated. The three common methods of treatment are substitution of one antidepressant drug for another, combination therapies and augmentation techniques. These are based on clinical experiences and not research findings. Therefore the treatment of TRD patients is more an art than a science. The physician should assess all the psychopathological, phenomenological and psychosocial variables to appropriately treat an individual patient.

show abstract

Section: Treatmentmentioning

confidence: 99%

Treatment-Resistant Depression

Ananth

1998

Psychother Psychosom

View full text Add to dashboard Cite

show abstract

“…The utility of fluoxetine in patients with a history of TCA nonresponse has been subsequently demonstrated in two controlled trials ( Table 1) (Reimherr et al, 1984;Beasley et al, 1990). Response rates of 43% and 51% were observed.…”

Section: Switching From a Tca To An Ssrimentioning

confidence: 97%

Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

et al. 1994

View full text Add to dashboard Cite

Only about 60-70% of those depressed patients who can tolerate an antidepressant medication, and only about SO-60% of those who begin a medication will respond to the Frst trial. Furthemnore, S-10% will remain depressed despite multiple medication trials. When the disorder is poorly responsive, it is variously described as a resistant, refractory, or intractable depression. This review summarizes the available literature on treatment-resistant depression (TRD) to provide recommendations for the most rational alternative strategies. Depression 2: 1S2-168 (1994/1995). @ 199s Wiley-Liss, Inc.

show abstract

“…Selective Serotonin Re-Uptake Inhibitors (SSRIs). A new and more selective generation of antidepressants was introduced beginning in the middle of the 1980s (Beasley et al, 1990). These medications, the SSRIs, include fluoxetine, paroxetine, sertraline, citalopram, and fluvoxamine.…”

Section: Pharmacotherapeutic Treatment Of Depressionmentioning

confidence: 99%

Review of the diagnosis and treatment of major depression for the non‐mental health professional

Rapaport

Judd²

1995

Depression

View full text Add to dashboard Cite

This paper is a review of the diagnosis and treatment of major depression for health professionals and the public. It is designed to help non‐mental health professionals understand the important health and societal consequences of major depression. And, it serves as a guide to help health professionals make the diagnosis of major depression and explore treatment options with patients. Depression 3:108–120 (1995). © 1995 Wiley‐Liss, Inc.

show abstract

Fluoxetine in tricyclic refractory major depressive disorder

Cited by 48 publications

References 8 publications

Treatment-Resistant Depression

Treatment-Resistant Depression

Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

Review of the diagnosis and treatment of major depression for the non‐mental health professional

Contact Info

Product

Resources

About